IVIG To SCIG Transition denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to the IVIG-to-SCIG Transition

Blue Cross Blue Shield step-therapy requirements sometimes apply to immunoglobulin therapy by requiring a trial of one or more formulary-preferred products before the requested product will be covered. In the context of an IVIG-to-SCIG transition, step therapy can arise when the plan requires evidence of a trial of a specific SCIG product before covering the prescriber's preferred brand, or — less commonly — when the plan's system does not recognize the patient's IVIG history as satisfying a step-therapy requirement for immunoglobulin therapy generally. The latter situation is particularly worth challenging, because most step-therapy policies include a step-therapy exception for patients who are already established on therapy.

## Why This Denial Is Appealable

Many states have enacted step-therapy override laws requiring insurers to grant exceptions when a patient has already tried and failed the required prior therapy, when the required step is contraindicated, or when it is otherwise clinically inappropriate. At the federal level, ACA §2719 provides for internal appeal and independent external review of step-therapy denials. ERISA §503 guarantees full-and-fair review for employer-plan members. File internally within the deadline on your EOB (typically 180 days) and, if denied, request external review within the standard 4-month window. Check whether your state's step-therapy override law applies to your plan type — if so, cite it in your appeal letter.

## The Concrete Appeal Process

1. Read the denial letter to identify exactly which step the plan says is missing. 2. Determine whether the patient's IVIG history satisfies that step — if so, the appeal is primarily documentation. 3. Research whether your state has a step-therapy exception statute and confirm whether it applies to your plan. 4. Have the prescriber write a step-therapy exception letter addressing the applicable exception criteria. 5. File the internal appeal; if denied, proceed to external review.

## Documentation to Gather

• IVIG treatment history: Complete records of the patient's IVIG therapy — start date, products used, duration, clinical response, and any tolerability issues — demonstrating that the patient is already established on immunoglobulin therapy.
• Prescriber step-therapy exception letter: Addresses the specific BCBS exception criteria (already tried a required step; required step is clinically inappropriate; required step would cause harm) with chart-specific facts for each criterion.
• Diagnosis and clinical status: Specialist notes confirming the ongoing diagnosis and medical necessity for immunoglobulin replacement.
• State step-therapy law reference: If applicable, cite the state statute in the appeal letter.
• FDA label for ordered product: Confirming approval for the patient's diagnosis.

## Criteria-Mapping Structure

Obtain the BCBS step-therapy policy and the exception criteria. Map each exception ground to chart evidence:

| Step-Therapy Exception Criterion | Chart / History Evidence | |---|---| | [Copy exact exception criterion — e.g., "patient previously tried required step therapy"] | [IVIG product, dates, prescriber attestation] | | [Copy exact exception criterion — e.g., "required step is clinically inappropriate"] | [Chart note, prescriber letter section] |

An established patient with a documented IVIG history is in the strongest possible position for a step-therapy exception, because the core purpose of step therapy — establishing clinical need through a trial — has already been fulfilled.